Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
By A. Keech, R. Simes, P. Barter, J. Best, Russel Scott, Marja-Riitta Taskinen, P. Forder, Avinesh Pillai, T. Davis, P. Glasziou and 9 more. The Lancet, 2005
3,034 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/e4cded1f476802a43e69fc260e87c27752caeb04
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- V. Basevi
- I. Graham
- Marja-Riitta Taskinen
- J. Forbes
- M. Cooper
- Silvio E. Inzucchi
- I. Hirsch
- M. S. Kirkman
In Surgery
- I. Graham
- Marja-Riitta Taskinen
- J. Forbes
- M. Cooper
- Silvio E. Inzucchi
- I. Hirsch
- M. S. Kirkman
- V. Basevi
Citations in the corpus
- The metabolic syndrome. (2003, neutral): “In contrast, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study enrolled nearly 10,000 people with type 2 diabetes mellitus and only achieved a nonsignificant 11% reduction in the primary end point [83].”
- Standards of Medical Care in Diabetes—2013 (2012, background): “However, in a large trial specific to diabetic patients, fenofibrate failed to reduce overall cardiovascular outcomes (296).”
- The metabolic syndrome. (2008, background): “of statins plus fibrates on CHD outcomes (604, 629).”